The Lobbying Register, read carefully Epicycle

Returns

Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.

Clear all

Showing returns naming Muiris O’Connor .

Filed returns
176
match these filters
Matching filed returns per period 0 5 10 15 20 Sep–Dec 2015: 10 filed returns Jan–Apr 2016: 4 filed returns May–Aug 2016: 4 filed returns Sep–Dec 2016: 10 filed returns Jan–Apr 2017: 5 filed returns May–Aug 2017: 2 filed returns Sep–Dec 2017: 5 filed returns Jan–Apr 2018: 3 filed returns May–Aug 2018: 4 filed returns Sep–Dec 2018: 3 filed returns Jan–Apr 2019: 8 filed returns May–Aug 2019: 3 filed returns Sep–Dec 2019: 1 filed returns Jan–Apr 2020: 1 filed returns May–Aug 2020: 1 filed returns Sep–Dec 2020: 7 filed returns Jan–Apr 2021: 7 filed returns May–Aug 2021: 3 filed returns Sep–Dec 2021: 7 filed returns Jan–Apr 2022: 4 filed returns May–Aug 2022: 3 filed returns Sep–Dec 2022: 3 filed returns Jan–Apr 2023: 6 filed returns May–Aug 2023: 3 filed returns Sep–Dec 2023: 6 filed returns Jan–Apr 2024: 2 filed returns May–Aug 2024: 9 filed returns Sep–Dec 2024: 6 filed returns Jan–Apr 2025: 10 filed returns May–Aug 2025: 4 filed returns Sep–Dec 2025: 5 filed returns Jan–Apr 2026: 16 filed returns May–Aug 2026: 11 filed returns 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Filed returns per four-month period Click a column to list its returns.
PeriodRegistrantPolicy areaSubject, as filedOfficials namedLink
May–Aug 2026 Rare Diseases Ireland Health Invitation to attend RDI's associated EU Presidency Event (Public policy or programme) 21 On lobbying.ie
May–Aug 2026 Takeda Products Ireland Health Engagements on life-sciences policy, innovation and competitiveness in Ireland and Europe (Public policy or programme) 12 On lobbying.ie
May–Aug 2026 Novartis Ireland Limited Health Valuing Innovation & Advanced Cancer Therapy - policy and access (Public policy or programme) 27 On lobbying.ie
May–Aug 2026 Novartis Ireland Limited Health Life Science Strategy (Public policy or programme) 4 On lobbying.ie
May–Aug 2026 Irish Pharmaceutical Healthcare Association Health Industry perspectives on access, innovation and coordination. (Public policy or programme) 1 On lobbying.ie
May–Aug 2026 Janssen Sciences Ireland UC Health Engagement with the Departments of Health and Enterprise regarding the national life science strategy (Public policy or programme) 5 On lobbying.ie
May–Aug 2026 Ibec Economic Development and Industry Inter-Ministerial Meeting convened in Royal College of Physicians (Public policy or programme) 6 On lobbying.ie
May–Aug 2026 Ibec Budgetary matters Irish Medtech Budget 2027 submission (Matters involving public funds) 20 On lobbying.ie
May–Aug 2026 Ibec EU Affairs European Health Data Space (EHDS) (Public policy or programme) 2 On lobbying.ie
May–Aug 2026 Centric Health Primary Care Limited Health Background information on who Centric Health are and what they do (Public policy or programme) 1 On lobbying.ie
May–Aug 2026 Pfizer Health Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) 16 On lobbying.ie
Jan–Apr 2026 Eli Lilly and Company Health Emerging trends in scientific research. (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2026 Janssen Sciences Ireland UC Economic Development and Industry Engagements with Irish policymakers on national life sciences policy (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2026 Eli Lilly and Company Health Emerging trends in scientific research. (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2026 The Irish Clinical Oncology Group t/a Cancer Trials Ireland Health John O'Neill, PO at DOH gave a presentation at a CTI event on the upcoming Biotech Act pursuant to clinical trials. John O'Neill deputised for Muiris O'Connor (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2026 The Irish Clinical Oncology Group t/a Cancer Trials Ireland Health Sent letter to Asst Sec Muiris O'Connor DOH seeking his participation in a stakeholder meeting on March 20th concerning the upcoming Biotech Act (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2026 MSD EU Affairs Ireland’s EU Council Presidency (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2026 Irish Pharmaceutical Healthcare Association Health Medicines Shortage - Provision in proposed EU General Pharmaceutical Legislation regarding medicines shortages prevention plan. (Legislation) 1 On lobbying.ie
Jan–Apr 2026 Irish Pharmaceutical Healthcare Association Health Industry position on a National Life Sciences Strategy (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2026 Irish Pharmaceutical Healthcare Association Health (i) IPHA priorities for EU Presidency and (ii) EU Presidency Events (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2026 Takeda Products Ireland Health National Life Science Strategy engagements (Public policy or programme) 3 On lobbying.ie
Jan–Apr 2026 Dexcom Health Diabetes Policy in Ireland (Public policy or programme) 43 On lobbying.ie
Jan–Apr 2026 Novartis Ireland Limited Health National Life Sciences Strategy (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2026 Ibec Economic Development and Industry National Life Sciences Strategy (Public policy or programme) 4 On lobbying.ie
Jan–Apr 2026 Ibec Economic Development and Industry Ireland’s National Life Sciences Strategy (Public policy or programme) 3 On lobbying.ie
Jan–Apr 2026 Rare Diseases Ireland Health Rare Diseases at the EU Presidency (Public policy or programme) 4 On lobbying.ie
Jan–Apr 2026 Pfizer Health Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) 16 On lobbying.ie
Sep–Dec 2025 Rare Diseases Ireland Health Seeking to highlight rare diseases during Ireland's EU Presidency in 2026 with an official event during the presidency (Public policy or programme) 4 On lobbying.ie
Sep–Dec 2025 Janssen Sciences Ireland UC Health Engagement with the Department of Health on the Life Sciences Strategy (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2025 SSLF Progress Ireland Education and Training Advanced market commitments (Matters involving public funds) 1 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health Advocate for Life Science Strategy (Public policy or programme) 7 On lobbying.ie
Sep–Dec 2025 Ibec EU Affairs Medical Technologies Regulation (MDR & IVDR - Impact on healthcare & innovation in Europe) (Legislation) 2 On lobbying.ie
May–Aug 2025 Rare Diseases Ireland Health Seeking to highlight rare diseases during Ireland's EU Presidency in 2026 with an official event during the presidency (Public policy or programme) 35 On lobbying.ie
May–Aug 2025 Illumina Cambridge Ltd Health National Genomics Strategy (Public policy or programme) 1 On lobbying.ie
May–Aug 2025 Ibec Health National Clinical Trials Office (Public policy or programme) 4 On lobbying.ie
May–Aug 2025 BearingPoint Ireland Health Sharing insights on international learnings of successful practices in health electronic data interchange and AI adoption. (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2025 Irish Pharmaceutical Healthcare Association Health Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on access to medicines in EU smaller countries/markets and intellectual property rights. (Public policy or programme) 3 On lobbying.ie
Jan–Apr 2025 Irish Pharmaceutical Healthcare Association Health Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) 12 On lobbying.ie
Jan–Apr 2025 Novo Nordisk Limited Health Engagement with Government, MEPs and public officials regarding the life-sciences sector in Ireland and the EU General Pharmaceutical Legislation (GPL) including two roundtable events. (Public policy or programme) 12 On lobbying.ie
Jan–Apr 2025 Alliance of Medicines for Ireland Company Limited by Guarantee Health Correspondence to relevant stakeholders regarding MFI event 'Digital Solutions for a Greener Industry'. (Public policy or programme) 13 On lobbying.ie
Jan–Apr 2025 Adelaide Health Foundation Health CEO met with Mr Muiris O'Connor, asst Sec Gen Department of Health on the 10th March 2025 to discuss AHF research project recommendations. (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2025 Ibec Economic Development and Industry Retaliatory Tariffs: Impact on healthcare in Europe (Public policy or programme) 11 On lobbying.ie
Jan–Apr 2025 Social Justice Ireland Public Expenditure and Reform Letter with a copy of Social Justice Matters 2025 sent with a request for a meeting. (Public policy or programme) 57 On lobbying.ie
Jan–Apr 2025 Irish Platform for Patients' Organisations, Science and Industry Health National developments/updates in relation to digital health, AI, health information management (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2025 Think Research Corporation Health Communicate the benefits of mandatory incident management (medication error) reporting for pharmacies in Ireland (Public policy or programme) 1 On lobbying.ie
Jan–Apr 2025 Irish Platform for Patients' Organisations, Science and Industry Health The Use of Artificial Intelligence (AI) in Healthcare in Ireland (Public policy or programme) 6 On lobbying.ie
Sep–Dec 2024 The Irish Clinical Oncology Group t/a Cancer Trials Ireland Health GCIG - International gynaecological conference (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2024 The Irish Clinical Oncology Group t/a Cancer Trials Ireland Health GCIG - International gynaecological conference (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2024 Irish Pharmaceutical Healthcare Association Health EU Commission proposed revision of the EU General Pharmaceutical Legislation and related matters, with particular attention to intellectual property rights provisions, competitiveness and regulatory affairs. (Legislation) 8 On lobbying.ie
Sep–Dec 2024 Pfizer EU Affairs EU Pharmaceutical Legislation proposals (Legislation) 6 On lobbying.ie

Policy areas in these returns

Public policy areaFiled returnsShareRelative to the largest
Health 141 80.1%
EU Affairs 7 4.0%
Public Expenditure and Reform 7 4.0%
Economic Development and Industry 6 3.4%
Communications 3 1.7%
Education and Training 3 1.7%
Trade 3 1.7%
Children and Youth Affairs 2 1.1%
Budgetary matters 1 0.6%
Employment 1 0.6%
Foreign Affairs 1 0.6%
Gaeltacht 1 0.6%